SLC5A2 and heart failure: Sodium glucose co-transporter 2 (SGLT-2) inhibitors, gliflozins, initially FDA- and EMA-approved for the treatment of diabetes mellitus, have recently been recommended as first-line treatment for heart failure with reduced ejection fraction by several international cardiac societies (4–6).